Abstract
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
Keywords: COVID-19; Cardiovascular; Drug–drug interactions; Pharmacotherapy; SARS-Cov2; Venous thromboembolism.
【저자키워드】 COVID-19, SARS-CoV2, Venous Thromboembolism, cardiovascular, pharmacotherapy, Drug–drug interactions, 【초록키워드】 Dexamethasone, Treatment, coronavirus disease, SARS-CoV-2, coronavirus, therapy, Mortality, Hydroxychloroquine, SARS-COV-2 infection, Remdesivir, cardiovascular disease, drug, severe acute respiratory syndrome Coronavirus, Venous Thromboembolism, protease inhibitors, heart failure, COVID-19 infection, myocarditis, morbidity, Patient, Thromboembolism, pharmacotherapy, medication, disease, Arrhythmias, 2019, anti-inflammatory agents, Acute coronary syndrome, Evidence, Interaction, cardiovascular complications, Health Organization, World Health Organization, cardiovascular complication, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, increased risk, problem, Administered, caused, approved, healthy individual, coronary syndrome, patients with COVID-19, 【제목키워드】 Complication,